CLINICAL AND PHARMACEUTICAL
Management of Diseases

AN EASY APPROACH TO THE CLINICAL SERVICES, PHARMACEUTICAL CARE, THERAPEUTICAL DRUG MONITORING, RISK/PROBLEMS SOLVING AND COMPLICATIONS OF POLY-PHARMACY

TAHA NAZIR
CLINICAL AND PHARMACEUTICAL
MANAGEMENT OF
DISEASES

1st Edition

TAHA NAZIR
B.Pharm.(PU), R.Ph.
M.Phil. (Pharmacology)
Ph.D. (Microbiology) Scholar

DOGAR PUBLISHER
35 Urdu Bazar, Lahore, Pakistan
dogar_publishers@yahoo.com
www.dogarpublisher.com
Compiled by:

TAHA NAZIR
Department of Pharmacy
University of Sargodha,
Sargodha 40100 Pakistan
taha.nazir@uos.edu.pk

Contributors

Furqan K. Hashmi B.Pharm., MSc., University of The Punjab, Lahore
Javed Iqbal B.Pharm, M.Phil., PhD., University of Balochistan, Quetta.
Syed Umer Jan B.Pharm., M.Phil, University of Balochistan, Quetta.
Fazl-E-Subhan B.Pharm., M.Phil., Ph.D., University of the Pashawar, Pashawar
Ashfaq Ahmad Mehr B.Pharm., M.Pharm., The University of Lahore, Lahore
Tahir Aziz Mugha B.Pharm., M.Phil., Ph.D., Shaukat Khanum Cancer Hospital & Research Centre, Lahore.
Muhammad Shoaiak Akhtar Ph.D., University of Sargodha, Sargodha
Nida Taha Pharm D., University of Sargodha, Sargodha
Azher Hussain B.Pharm., M.Phil, Hamdard University, Islamabad
Mian Riffat Ul Zaman PhD, Islamia University, Bahawalpur
Ayaz Ali Khan B.Pharm., M.Pharm., Lahore College of Pharmaceutical Sciences, Lahore
Allah Buksh Awan B.Pharm., M.Sc., Molecular Biology, GC University, Faisalabad.
Shoukat Mustafa B.Pharm., M.Phil., The University of Faisalabad, Faisalabad.
Miss. Samreen Pharm D., M.Phil., Lahore College of Pharmaceutical Sciences, Lahore

1st Edition, 2009

All rights reserved, Dogar Publisher

This book, or any parts thereof, may not be reproduced or stored in an information retrieval network without the written permission of the author or publisher. The readers are advised to consult the clinical pharmacist and other references before using any therapeutic agent. The author and publisher disclaim any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this text.
DEDICATED TO MY

✦ FATHER; M. NAZIR CHAHL
✦ WIFE; NIDA TAHA
✦ SON; ABDULLAH TAHA
✦ SON; ARSALAN TAHA AND
✦ RESPECTED TEACHERS

TAHA NAZIR
NOTICE

The therapy plans and clinical profiles of therapeutical agents are being changed every day. Pharmaceutical research and clinical trails have sharply broadened our knowledge and making more sophisticated alterations in treatment protocols. The author, contributors and publisher of this manuscript have checked the informations with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standard accepted at the time of publication. However, in view of the possibility of human error or change in latest clinical research data, neither the author nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contain herein is in every respect accurate or compete, and they disclaim all responsibility for any error or omissions or for the results obtained from use of the information contained in this work. The students, researchers and readers are encouraged to confirm the information contains herein and this recommendation is of particular importance in connection with newer or infrequently used drugs.
## CONTENTS

<table>
<thead>
<tr>
<th>Chapter No.</th>
<th>Title</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>UNIT I</strong></td>
<td><strong>CLINICAL MANAGEMENT OF CARDIOVASCULAR DISEASES</strong></td>
<td>1</td>
</tr>
<tr>
<td>Chapter 1:</td>
<td>Clinical management of Arrhythmia</td>
<td>2</td>
</tr>
<tr>
<td>Chapter 2:</td>
<td>Clinical management of Hypertension</td>
<td>36</td>
</tr>
<tr>
<td>Chapter 3:</td>
<td>Clinical management of Heart failure, Cardiomyopathy and Minor heart diseases</td>
<td>48</td>
</tr>
<tr>
<td>Chapter 4:</td>
<td>Clinical management of Ischemic Heart disease</td>
<td>71</td>
</tr>
<tr>
<td>Chapter 5:</td>
<td>Clinical management of ST-Elevated Myocardial Infarction</td>
<td>89</td>
</tr>
<tr>
<td>Chapter 6:</td>
<td>Clinical management of Valvular Heart disease</td>
<td>92</td>
</tr>
<tr>
<td>Chapter 7:</td>
<td>Clinical management of Syncope</td>
<td>110</td>
</tr>
<tr>
<td>**UNIT II:</td>
<td><strong>CLINICAL AND PHARMACEUTICAL MANAGEMENT OF INFECTIOUS DISEASES</strong></td>
<td>117</td>
</tr>
<tr>
<td>Chapter 1:</td>
<td>Clinical and pharmaceutical management of infectious diseases</td>
<td>117</td>
</tr>
<tr>
<td>Chapter 2:</td>
<td>Clinical and pharmaceutical management of Fever and Febrile syndrome</td>
<td>147</td>
</tr>
<tr>
<td>Chapter 3:</td>
<td>Clinical and pharmaceutical management of Neural infections</td>
<td>175</td>
</tr>
<tr>
<td>Chapter 4:</td>
<td>Clinical and pharmaceutical management of infections of the Upper Respiratory Tract</td>
<td>196</td>
</tr>
<tr>
<td>Chapter 5:</td>
<td>Clinical and pharmaceutical management of infections of the Lower Respiratory Tract</td>
<td>210</td>
</tr>
<tr>
<td>Chapter 6:</td>
<td>Clinical and pharmaceutical management of Heart and Vessels infections</td>
<td>238</td>
</tr>
<tr>
<td>Chapter 7:</td>
<td>Clinical and pharmaceutical management of Skin, Muscle and Soft tissues infections</td>
<td>253</td>
</tr>
<tr>
<td>Chapter 8:</td>
<td>Clinical and pharmaceutical management of Intra-abdominal abcess and peritonitis</td>
<td>264</td>
</tr>
<tr>
<td>Chapter 9:</td>
<td>Clinical and pharmaceutical management of infectious Diarrhea</td>
<td>281</td>
</tr>
<tr>
<td>Chapter 10:</td>
<td>Clinical and pharmaceutical management of Sexually transmitted diseases</td>
<td>291</td>
</tr>
<tr>
<td>Chapter 11:</td>
<td>Clinical and pharmaceutical management of Nosocomial infections</td>
<td>309</td>
</tr>
<tr>
<td>Chapter 12:</td>
<td>Clinical and pharmaceutical management of bacteremia and sepsis</td>
<td>315</td>
</tr>
<tr>
<td>Chapter 13:</td>
<td>Clinical and pharmaceutical management of Bones and Joints infections</td>
<td>320</td>
</tr>
</tbody>
</table>
NOTICE

The therapy plans and clinical profiles of therapeutical agents are being changed every day. Pharmaceutical research and clinical trails have sharply broadened our knowledge and making more sophisticated alterations in treatment protocols. The author, contributors and publisher of this manuscript have checked the informations with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standard accepted at the time of publication. However, in view of the possibility of human error or change in latest clinical research data, neither the author nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contain herein is in every respect accurate or compete, and they disclaim all responsibility for any error or omissions or for the results obtained from use of the information contained in this work. The students, researchers and readers are encouraged to confirm the information contains herein and this recommendation is of particular importance in connection with newer or infrequently used drugs.
PREFACE

The poor clinical practice for managing the diseased conditions needs an integrated and valid collection of simple and conceptual literature. Moreover, the pharmacy discipline is present in pre-established form in developing part of the world. It has been therefore tried to elaborate the basics of clinical practice. It is carefully tried to provide the latest and established treatment protocols which helps to improve the patient care and minimize the complications of poly-pharmacy/ multi disease therapies.

The substandard clinical and pharmaceutical services throw in like a terrible monster in health care system that works like an invisible vampire. The therapeutical problems, drug interactions, adverse drug reactions, formulation errors, conversion mistakes, drug abuse, ineffectiveness and non-compliance would continue there mortalities and morbidities until or unless conceived and corrected properly. The clinical pharmacist and drug experts have to play their role to assure the implementation and monitoring of treatment plans. Developments of such professional skills need a comprehensive and collaborative relationship to produce an integrated and professional attitude/ values. Such a structured learning process will help to improve overall clinical and pharmaceutical services. The "Management of Diseases’ is therefore compiled to fulfill the requirement of learners. The material contain herein facilitates an in-depth level of understanding of essential therapeutical/ clinical activities.

The valuable feedback and constructive suggestions will warmly be welcomed

At last, but not least, I have utmost pleasure to express the heartiest gratitude to my teachers, wife and students for support, help and persuasively striving to bring this work fruitfully conclusive.

TAHA NAZIR
Dept. of Pharmacy
University of Sargodha
Sargodha, Pakistan
tahanazir@yahoo.com

4th August, 2009